Citations

Showing 10 of 108119 citations.

Leaflet Tissue Generation from Microfibrous Heart Valve Leaflet Scaffolds with Native Characteristics
Jana, Soumen , Morse, David , Lerman, Amir , Lerman, Amir , Morse, David

Mayo Clinic

ACS Applied Bio Materials | November 3, 2021 | Volume: 4 | Issue: 11 | Pages: 7836-7847

10.1021/acsabm.1c00768 | PMID 35006765 Get It

Reliability of 3‐dimensional surface imaging of the face using a whole‐body surface scanner
Xu, Ya , Frank, Konstantin , Kohler, Lukas , Ehrl, Denis , Alfertshofer, Michael , Giunta, Riccardo Enzo , Moellhoff, Nicholas , Cotofana, Sebastian , Koban, Konstantin Christoph , Giunta, Riccardo E. , Cotofana, Sebastian , Alfertshofer, Michael , Giunta, Riccardo Enzo , Moellhoff, Nicholas

Mayo Clinic

Journal of Cosmetic Dermatology | November 3, 2021 | Volume: 21 | Issue: 4 | Pages: 1464-1470

10.1111/jocd.14555 | PMID 34731521 Get It

AbstractObjectiveTo the knowledge of the authors, no data about the reproducibility and accuracy of 3‐dimensional surface imaging of the face using a whole‐body scanner are available. Thus, the objective of this investigation was to assess the reproducibility of facial scans acquired using a whole‐body imaging device.Material and MethodsThis investigation investigated 220 3‐D scans of a total of 22 healthy volunteers (with a mean age of 29.36 years). Two consecutive 3‐D images using a Vectra WB360 of the volunteers were obtained utilizing a whole‐body imaging device. Predefined distances in the face were performed in each scan and compared. Furthermore, surface deviation between two consecutively captured scans was assessed.ResultsThe distance with the smallest statistical significance was found to be at the nose with p = 0.998, while the biggest statistical significance was found in the midface with p = 0.658. The area with the biggest surface deviation between the superimposed scans was the neck with a root mean square (RMS) of 1.62 ± 1.71, and the area with the smallest surface deviation was the forehead with a RMS of 0.17 ± 0.05.ConclusionThe whole‐body imaging device investigated in this study can be utilized to capture the face and provides enough accuracy to compare scans. Even though not directly investigated, it can be hypothesized that the error caused by repositioning the patient between a baseline and a follow‐up scan will not be too big to consider measurements performed with the whole‐body imaging device as impractical.
Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy
Aghali, Arbi

Mayo Clinic

Cells | November 3, 2021 | Volume: 10 | Issue: 11 | Pages: 2993

10.3390/cells10112993 | PMID 34831216 Get It

Craniofacial bone defects can result from various disorders, including congenital malformations, tumor resection, infection, severe trauma, and accidents. Successfully regenerating cranial defects is an integral step to restore craniofacial function. However, challenges managing and controlling new bone tissue formation remain. Current advances in tissue engineering and regenerative medicine use innovative techniques to address these challenges. The use of biomaterials, stromal cells, and growth factors have demonstrated promising outcomes in vitro and in vivo. Natural and synthetic bone grafts combined with Mesenchymal Stromal Cells (MSCs) and growth factors have shown encouraging results in regenerating critical-size cranial defects. One of prevalent growth factors is Bone Morphogenetic Protein-2 (BMP-2). BMP-2 is defined as a gold standard growth factor that enhances new bone formation in vitro and in vivo. Recently, emerging evidence suggested that Megakaryocytes (MKs), induced by Thrombopoietin (TPO), show an increase in osteoblast proliferation in vitro and bone mass in vivo. Furthermore, a co-culture study shows mature MKs enhance MSC survival rate while maintaining their phenotype. Therefore, MKs can provide an insight as a potential therapy offering a safe and effective approach to regenerating critical-size cranial defects.
Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group
Garcia, Michael A. , Johnson, Shelsey W. , Sisson, Emily, Sheldrick, Christopher R., Kumar, Vishakha K. , Boman, Karen , Bolesta, Scott , Bansal, Vikas , Domecq, J. P., Lal, Amos , Christie, Amy B. , Sanghavi, Devang , Vadgaonkar, Girish, Investigators, for the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study, Kaur, Nirmaljot , Camazine, Maraya , Заболотских, И. Б. , Asghar, Muhammad Sohaib , Lal, Amos , Bansal, Vikas , Kaur, Nirmaljot , Asghar, Muhammad S , Domecq Graces, Juan Pablo , Bosch, Nicholas A. , Sheldrick, Christopher R., Deo, Neha , Banner‐Goodspeed, Valerie , Gajic, Ognjen , Kashyap, Rahul , Walkey, Allan J. , Investigators, for the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study

Mayo Clinic

Critical Care Explorations | November 3, 2021 | Volume: 3 | Issue: 11 | Pages: e0566

10.1097/cce.0000000000000566 | PMID 34746796 Get It

IMPORTANCE: At the start of the coronavirus disease 2019 pandemic, medications repurposed for management of coronavirus disease 2019 were used in the absence of clinical trial evidence. OBJECTIVES: To describe the variation and evolution in use of repurposed medications for coronavirus disease 2019. DESIGN, SETTING, AND PARTICIPANTS: Observational cohort study of adults hospitalized with coronavirus disease 2019 between February 15, 2020, and April 12, 2021, across 76 United States and international hospitals within the Society of Critical Care Medicine’s Discovery Viral Infection and Respiratory Illness Universal Study coronavirus disease 2019 registry. MAIN OUTCOMES AND MEASURES: Hospital variation was quantified using multivariable adjusted random effects logistic regression models and unsupervised clustering. Repurposed medications included antivirals, corticosteroids, hydroxychloroquine, immunomodulators, and therapeutic dose anticoagulants. RESULTS: Among 7,069 adults hospitalized with coronavirus disease 2019, 1,979 (28%) received antivirals, 2,876 (41%) received corticosteroids, 1,779 (25%) received hydroxychloroquine, 620 (9%) received immunomodulators, and 2,154 (31%) received therapeutic dose anticoagulants. Contribution of hospital site to risk-adjusted variation was 46% for antivirals, 30% for corticosteroids, 48% for hydroxychloroquine, 46% for immunomodulators, and 52% for therapeutic dose anticoagulants. Compared with the early pandemic, the later pandemic practice phenotypes converged with increased use of antivirals (odds ratio, 3.14; 95% CI, 2.40–4.10) and corticosteroids (odds ratio, 5.43; 95% CI, 4.23–6.97), with decreased use of hydroxychloroquine (odds ratio, 0.02; 95% CI, 0.01–0.04) and immunomodulators (odds ratio, 0.49; 95% CI, 0.34–0.70). There was no clinically significant change in the use of therapeutic dose anticoagulants (odds ratio, 1.01; 95% CI, 1.01–1.02). There were no differences in risk-adjusted mortality between hospitals with high rates of repurposed medication use compared with hospitals with low rates of use. CONCLUSIONS AND RELEVANCE: Hospital variation in the use of repurposed medications varied widely across hospitals early in the pandemic and later converged with the emergence of randomized clinical trials. Platforms developed for rapid activation and enrollment in clinical trials of repurposed medications are needed prior to the next pandemic to expedite effective, evidence-based practice.
Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document
Greninger, Alexander L. , Bard, Jennifer Dien , Colgrove, Robert C. , Graf, Erin H. , Hanson, Kimberly E. , Hayden, Mary K. , Humphries, Romney M. , Lowe, Christopher F. , Pillai, Dylan R. , Rhoads, Daniel D. , Yao, Joseph D. , Lee, Francesca M, Dien Bard, Jennifer , Humphries, Romney , Hanson, Kimberly , Rhoads, Daniel D , Greninger, Alexander L , Graf, Erin H , Miller, Melissa B.

Mayo Clinic

Journal of Clinical Microbiology | November 3, 2021 | Volume: 60 | Issue: 1 | Pages: No page available

10.1128/jcm.01659-21 | PMID 34731022 Get It

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution.
Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction
Givertz, Michael M. , Shah, Palak , McNulty, Steven E., Anstrom, Kevin J. , Mahr, Claudius , Gupta, Divya , Redfield, Margaret M. , Lala, Anuradha , Desvigne‐Nickens, Patrice , Braunwald, Eugene, Investigators, LIFE, Mohammed, Selma F. , Birru, Hellina, Aboye, Etsubdink, Lam, Phillip H. , Escobar, Nicole, Fink, Maria Cristina Domingues , Cappola, Thomas P. , Sheaffer, Wendy , Reilly, Bonitta, Ferree, J W, Ciezkowski, Gina, Herrera, Glenda, Mehta, Hirsch, Delucca, Rosemarie, Doddamani, Sanjay , Thomas, B. , Machen, Laurie, Kim, J., Christina, Athas, Lampert, Brent C. , Fontenelle, Cindy, Eiswirth, Clement, Rock, Darlene, Egnaczyk, Gregory F. , Rentas-Sherman, Enya, Barr, Deborah, Damato, Adrianna, Calayo, Christine, Herre, John M. , Carroll, Amanda , Keebler, Mary , Setliff, Bandaa, Gulati, Sanjeev , Winkler, K, Curtin, Laura, Ohmart, Carly, Halvorson, John, Mudd, James O., Camacho, S. Albert , Palardy, Maryse , Shah, Neha, Picardi, Kristina, Krishnamoorthy, Arun, Maximin, Adrienne, Horstmanshof, Douglas , Seiler, Beverly, Xu, Zi J., Mersola, S., Kransdorf, E. , Fonk, T., Oliveira, Guilherme H., Semenec, Terrence, Leo, Peter , Dunlap, Mark E. , Felker, G. Michael , Taylor, Lacey D., Sheehan, Mary, Levine, Sharon, Cocca-Spofford, Diane, Brooks, Liana, Cunningham, Thomas F., Acker, Nancy, Milbrandt, Susan, Gatzke, Janet, Dávila‐Román, Víctor G. , Bult, Karen, Weber, Elizabeth, Lesko, Mary, Mikhalkova, Deana , Fitzgerald, Kathleen, Whellan, David J. , Gutierrez, Jonathan, Goldsborough, Yavette, Caikauskaite, Indre, Skopicki, Hal A. , Huggins, Gordon S. , Yuen, Nathan, Haynes, Abbey, Katie, Carr, Snell, Gail, Smith, Andrew L. , Walker, Brandon S. , JOHNSON, J. Y. M., Henderson, Simmone, Pauwaa, Sunil, Bhat, Geetha , Gagliardi, A.R.T., Mann, Douglas L. , Vader, Justin M. , Starling, Randall C. , Margulies, Kenneth B. , Kiernan, Michael S. , Lewis, Gregory D. , DeVore, Adam D. , Hernandez, Adrian F. , Braunwald, Eugene , Investigators, LIFE, Aboye, Etsubdink A, Fink, Maria, Ferree, Jenny, Ravichandran, Ashwin Kumar , Herrera, Glenda, Kanwar, Manreet , Williams, Julie , Bhimaraj, Arvind , Lindenfeld, JoAnn , Gordon, Mary Ellen , Gulati, Sanjeev K., Winkler, Krystal, Tang, W.H. Wilson , Gorodeski, Eiran Z. , Norton, Nadine , Nichols, Julie, Taylor, Lacey, Cunningham, Thomas, Dirks, Anne, Wever‐Pinzon, Omar , Gilotra, Nisha A , Walker, Brandon, Henderson, Simmone, Gagliardi, Ann, Shah, Palak

Mayo Clinic

JAMA Cardiology | November 3, 2021 | Volume: 7 | Issue: 1 | Pages: 17

10.1001/jamacardio.2021.4567 | PMID 34730769 Get It

A novel meniscofemoral ligament variant intra‐substance to the PCL
Verhey, Jens T. , Deckey, David G. , Dulle, Donald L., Long, Jeremiah R. , Miller, Mark D. , Tummala, Sailesh, Hassebrock, Jeffrey D. , Dulle, Donald, Tummala, Sailesh V , Tummala, Sailesh V. , Chhabra, Anikar

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | November 3, 2021 | Volume: 30 | Issue: 7 | Pages: 2277-2280

10.1007/s00167-021-06791-6 | PMID 34734309 Get It

AbstractWhile much detail is known about each anatomic structure of the knee and its contributory effect on biomechanics, our understanding is still evolving. In particular, the function of the meniscofemoral ligaments and their anatomical variants have yet to be fully described. In this report, a never‐before‐described anatomical meniscofemoral ligament variant intra‐substance to the PCL is presented. Arthroscopists should be aware of the novel variant as a growing number of studies have demonstrated the biomechanical importance of the meniscofemoral ligaments in protecting the lateral meniscus and supporting the function of the PCL.Level of Evidence: IV.
Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology
Watts, Andrew J.B. , Keller, Keith H. , Lerner, Gabriel, Rosales, Ivy, Collins, A. Bernard, Sekulic, Miroslav , Waikar, Sushrut S. , Chandraker, Anil, Alexander, Mariam P. , Troost, Jonathan P., Chen, Junbo, Fermin, Damian , Yee, Jennifer L., Sampson, Matthew G., Henderson, Joel M., Greka, Anna, Rennke, Helmut G., Weins, Astrid, Henderson, Joel , Riella, Leonardo V , Alexander, Mariam P , Fermin, Damian , Beck, Laurence H , Watts, Andrew J.B. , Keller, Keith H. , Lerner, Gabriel, Rosales, Ivy, Collins, A. Bernard, Sekulic, Miroslav , Waikar, Sushrut S. , Chandraker, Anil, Troost, Jonathan P., Chen, Junbo, Yee, Jennifer L., Sampson, Matthew G., Henderson, Joel M., Greka, Anna, Rennke, Helmut G., Weins, Astrid

Mayo Clinic

Journal of the American Society of Nephrology | November 3, 2021 | Volume: 33 | Issue: 1 | Pages: 238-252

10.1681/asn.2021060794 | PMID 34732507 Get It

Significance Statement Although corticosteroids are an effective first-line therapy for minimal change disease, relapse, steroid dependence, and intolerance are common in this podocytopathy of unknown etiology. The efficacy of B cell–targeted therapies in some patients suggests an autoantibody-mediated etiology. This study describes the novel discovery in both adults and children with minimal change disease of autoantibodies targeting nephrin, a critical component of the podocyte slit diaphragm that ensures integrity of the glomerular filtration barrier. This observation aligns with the established proteinuric effect of antinephrin antibodies demonstrated in animal models. These findings identify an important autoimmune mechanism in a subset of patients with minimal change disease and provide a framework for the application and development of precision medicine strategies in this condition. Background Failure of the glomerular filtration barrier, primarily by loss of slit diaphragm architecture, underlies nephrotic syndrome in minimal change disease. The etiology remains unknown. The efficacy of B cell–targeted therapies in some patients, together with the known proteinuric effect of anti-nephrin antibodies in rodent models, prompted us to hypothesize that nephrin autoantibodies may be present in patients with minimal change disease. Methods We evaluated sera from patients with minimal change disease, enrolled in the Nephrotic Syndrome Study Network (NEPTUNE) cohort and from our own institutions, for circulating nephrin autoantibodies by indirect ELISA and by immunoprecipitation of full-length nephrin from human glomerular extract or a recombinant purified extracellular domain of human nephrin. We also evaluated renal biopsies from our institutions for podocyte-associated punctate IgG colocalizing with nephrin by immunofluorescence. Results In two independent patient cohorts, we identified circulating nephrin autoantibodies during active disease that were significantly reduced or absent during treatment response in a subset of patients with minimal change disease. We correlated the presence of these autoantibodies with podocyte-associated punctate IgG in renal biopsies from our institutions. We also identified a patient with steroid-dependent childhood minimal change disease that progressed to end stage kidney disease; she developed a massive post-transplant recurrence of proteinuria that was associated with high pretransplant circulating nephrin autoantibodies. Conclusions Our discovery of nephrin autoantibodies in a subset of adults and children with minimal change disease aligns with published animal studies and provides further support for an autoimmune etiology. We propose a new molecular classification of nephrin autoantibody minimal change disease to serve as a framework for instigation of precision therapeutics for these patients.
Teaching Psychopharmacology in the Medically Ill: A Problem-Based Learning Card Game for Consultation-Liaison Psychiatry Didactics
Fipps, David C. , Rainey, Elisabet, Fipps, David C

Mayo Clinic

Journal of Medical Education and Curricular Development | November 3, 2021 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/23821205211041799 | PMID 34778563 Get It

INTRODUCTION Our educational report discusses a unique card game that provides an engaging, and competitive strategy for teaching psychopharmacology in the medically ill. It engages the players and helps them learn how to justify medical decisions in the context of complicated medical comorbidity. METHODS We describe a problem-based learning approach where learners are presented with randomized diagnoses and complications and are then forced to make prescription decisions for treatment from a limited and randomized supply of medication cards. Each round is facilitated by the teacher, who engages the teams and/or individual players in discussions regarding the rationale and justification of the medication decisions. These treatment plans are scored according to the appropriateness of the medication choice and the process is repeated. DISCUSSION The game is flexible regarding players’ levels of education and has been played by medical students, psychiatry residents, and fellows throughout their years of training. Overall feedback has been positive from facilitators and trainees and the game has been a valuable source of engaging learners in the process of making complex medication decisions in the medically ill.
Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L
Lu, Shao‐Chia , Hansen, Michael J. , Hemsath, Jack R. , Parrett, Brian J. , Zell, Brady N. , Barry, Michael A. , Barry, Michael A , Zell, Brady

Mayo Clinic

Human Gene Therapy | November 3, 2021 | Volume: 33 | Issue: 5-6 | Pages: 250-261

10.1089/hum.2021.197 | PMID 34731019 Get It

Oncolytic viruses (OVs) can have utility for direct killing of cancer cells, but may also serve to activate the immune system against cancer cells. While viruses alone can serve as immune stimulators, there is great interest in arming OVs with genes encoding immune stimulatory proteins to amplify their effects. In this work, we have tested the efficacy of conditionally-replicating adenoviruses (CRAds) with and without selected immunostimulatory payloads, murine CD40L (mCD40L) or 4-1BBL (m4-1BBL), in an immune competent mouse model of melanoma. When CRAd657-m4-1BBL and CRAd657-mCD40L were injected into B16-hCAR murine melanoma tumors, both single vectors delayed tumor growth and prolong survival compared to empty CRAd657. However, combined injection of both CRAd-m4-1BBL and CRAd-mCD40L mediated significantly better control of tumor growth. All of the payloads increased immune cell infiltration into tumors and notably reduced expression of PD-1 exhaustion marker on T cells. Tumor volumes were negatively associated with total infiltrating T cell population. We found that the payloads increased immune cell infiltration into tumors with some specificities: recruitment of CD8 + T cells was higher with m4-1BBL expression, while mCD40L expression induced more CD4 + T cell infiltration. Importantly, the combination of CRAd657-m4-1BBL and CRAd657-mCD40L induced the highest immune cells/T cell infiltration and the highest anti-TRP-2 tumor-associated antigen T cell responses than empty or single gene vector. This combination also caused depigmentation in areas adjacent to the tumor sites in more animals. These data indicate that driving two axes of the immune system with combined immune stimulatory payloads can lead to improved anticancer immune responses and better tumor control in an immune competent model of cancer.